Summary The bcl-2 gene encodes for a mitochondrial membrane proto-oncoprotein, the expression of which is known to suppress programmed cell death (apoptosis). In the present study the 
The bcl-2 gene encodes for a membrane-associated protein that is present in outer mitochondrial membrane. Additionally it was described in some parts of the endoplasmatic reticulum and nuclear envelope (Monaghan et al., 1992 ; Krajewski et al., 1993; Jacobson et al., 1993) . Expressed widely during embryonic development, in the adult it is confined to long-lived cells (e.g. stem cell populations, resting B lymphocytes, and peripheral neurones) (Hockenbery et al., 1991) . The biochemical function remains largely unknown, although bcl-2 oncoprotein is known to inhibit programmed cell death (for review see Reed, 1994) . Furthermore some data support a role in cell growth control via regulation of the redox system of cells (Hockenbery et al., 1993; Kane et al., 1993; Richter, 1993) . Recently a paradoxical inhibition of in vitro cell growth has been reported in several solid tumour cell lines (Pietenpol et al., 1994) .
The bcl-2 gene product was shown to be over-expressed in the 14;18 translocation of human B-cell lymphoma (Tsujimoto et al., 1985) , Hodgkin's disease, and reactive lymph nodes (Corbally et al., 1994) and was immunohistochemically demonstrated in breast carcinoma (Doglioni et al., 1994; Leek et al., 1994; Silvestrini et al., 1994) , follicular carcinoma of the thyroid (Pilotti et al., 1994a,b) , non-small-cell lung cancer (Pezzella et al., 1993) , hepatocellular carcinoma (Zhao et al., 1994) and neuroblastoma (Castle et al., 1993) Tumour tissues were routinely processed (formalin-fixed and paraffin-embedded) and were classified according to Dukes' classification (Dukes and Bussey, 1958) , with an added D-stage for patients with distant metastases, TNM staging system (Spiessl et al., 1992) and WHO grading system (Morson and Sobin, 1976) . Lymphocytic infiltration at the advancing edge of the tumour was determined according to the criteria of Jass et al. (1986) . PBS; 60 min at room temperature; Dianova, Hamburg, Germany). The bridging antibody and the APAAP complex were applied on a semiautomatic immunostaining device ('Omnibus'; Quartett, Berlin, Germany). Subsequently the enzyme reaction was developed for 25 min at room temperature in a freshly prepared new fuchsin solution containing naphtholbi-as-phosphate. Finally the sections were counterstained with haematoxylin and mounted in Kayser's glycerine gelatine. Omission of the primary antibody and replacement of the primary antibody by an inappropriate monoclonal antibody were used for negative control, and normal human tonsil tissues for positive control reactions.
Semiquantitative assessment of immunohistochemical staining patterns Semiquantitative evaluation was performed twice by one of the authors (KWS) with a 2 week interval. The staining was categorised as follows: no immunoreactive cells detectable (neg), fewer than 5% bcl-2 (+), 5-50% of tumour cells (+ +), and more than 50% (+ + +) positive cells. The semiquantitative evaluation was shown to be highly reproducible since no divergent diagnoses was made in the second assessment.
Patients'follow-up and statistical analysis All data were entered into a Macintosh IIci microcomputer and statistical analysis was carried out using the SYSTAT statistical package (Wilkinson, 1989) including the SUR-VIVAL supplementary module (Steinberg and Colla, 1988) . Patients were followed up according to the oncological Univariate and multivariate long-term survival analysis Figure 2 illustrates survival curves for all patients in the study with regard to bcl-2-negative and -positive immuno- bcl-2 expression with favourable clinical outcome. Similar results were previously reported on non-small-cell carcinomas of the lung (Pezzella et al., 1993) , breast carcinoma (Leek et al., 1994) and thyroid follicular carcinomas (Pilotti et al., 1994b) . As in these tumours, the classic cause of bcl-2 overexpression, namely 14;18 translocation, has not been found in colorectal carcinoma.
Our results showed that immunohistochemical bcl-2 demonstration was significantly associated with the pT stage but not with Dukes' classification or the development of lymph node and organ metastases. bcl-2 was detectable in more than 60% of cases with uneventful clinical course, whereas the majority of cases with the development of metastases (62%) and local recurrence (>90%) completely lacked immunohistochemically detectable bcl-2 protein. These findings support the concept that bcl-2 expression is related to slower local tumour growth. Thus, the better clinical outcome of these patients may simply be attributable to the prolonged period over which these tumours remain clinically detectable in their earlier stages of progression.
Normal tissues of organs with slow cell turnover rates are known to express bcl-2 protein (Hockenbery et al., 1991; Doglioni et al., 1994; Leek et al., 1994; Pilotti et al., 1994b) . In contrast to studies performed on carcinomas of the breast (60%) and carcinomas derived from thyroid follicular epithelium (approximately 80%), we found a considerably lower percentage of positive immunoreactive cases in colorectal cancer (45%). This most likely reflects biological differences between these tumour types. It is intriguing to see that, in contrast to the very advanced tumours of our series of colorectal carcinomas expressing bcl-2 (<5%), bcl-2 was detectable in more than 80% of poorly differentiated thyroid carcinomas (Pilotti et al., 1994a) .
In the studies on breast and thyroid carcinomas bcl-2 expression was shown to correlate with single favourable prognostic parameters. However, in colorectal cancer a statistically significant inverse association (P = 0.02; Table  III ) between bcl-2 expression and tumour size was found. Immunoreactivity for bcl-2 decreased from 80% (pTl tumours) to 20% (pT4 tumours) with progressive tumour size (compare Table III ). Pezzella et al. (1993) found in their study that survival of patients with bcl-2-positive non-smallcell carcinomas (80 squamous-cell and 42 adenocarcinomas) of the lung was statistically significantly higher. In colorectal cancer a similar association (P = 0.03) of bcl-2 immunoreactivity and clinical course of patients was found. Moreover it was proven in our study, that immunohistochemically detectable bcl-2 expression predicts patient survival independently in uni-and multivariate analysis (P = 0.001). Although of minor statistical significance (P = 0.04), a correlation of immunohistochemically demonstrated bcl-2 expression and lymphocytic infiltration patterns at the advancing edge of the tumour (Jass et al., 1986) was shown. Further research may prove whether bcl-2 expression may be associated with the biological background of lymphocytic infiltration.
Although the biological functions of bcl-2 protein are not yet fully understood, the present findings provide further evidence that immunohistochemically demonstrated bcl-2 oncoprotein appears to be associated with less aggressive tumour behaviour and/or may reflect different stages of tumour progression. However, it is not clear why bcl-2 expression seems to be associated with a favourable clinical outcome. Pietenpol et al. (1994) found that expression of bcl-2 in several solid tumour cell lines resulted in a paradoxical growth inhibition similar to that seen with p53. It has been suggested that bcl-2-promoted cell survival in slowly growing tumours may decrease the rate of acquiring complementary defects. Additionally bcl-2 oncoprotein regulates cell growth not only by inhibition of programmed cell death but also via the redox system of cells.
In summary we propose immunohistochemical bcl-2 expression to be an additional prognostic marker in colorectal carcinoma. Immunohistochemically demonstrated bcl-2 may even be an independent prognostic parameter with influence on post-operative therapeutic strategies. However, further research is necessary to elucidate the role of bcl-2 in cell and tumour growth control.
